New Study: Dermatologicals in the US

Dermatologicals had a very strong year in 2014, with current retail value sales increasing by 3%, marking the fastest single-year growth since 2007. The significant ageing of the US population has represented a factor contributing to accelerating growth over the past several years. The older demographic tends to have more frail skin, which is more susceptible to dermatological ailments. Topical antifungals, hair loss treatments, medicated shampoos, antipruritics and haemorrhoid treatments have benefited most from the ageing population. The increased prevalence of certain chronic diseases, especially diabetes and obesity, has also had a favourable impact on dermatologicals, especially those targeted for foot care.

Full Report Details at
- http://www.fastmr.com/prod/993674_dermatologicals_us.aspx?afid=301

Competitive Landscape

The dermatologicals competitive landscape continues to be closely contested by a number of companies. Johnson & Johnson maintains its leading position, holding a 16% retail value share through its diverse portfolio of leading brands in several dermatological sub-categories: Neutrogena T/Gel in medicated shampoos, Rogaine in hair loss treatments, Desitin in nappy (diaper) rash treatments, Aveeno in antipruritics, Tucks in haemorrhoid treatments, Benadryl in topical allergy remedies/antihistamines and Neosporin in topical germicidals/antiseptics. The next five largest global brand operators account for another 32% of retail value share, including Bayer (9%), Sanofi (7%), Pfizer (6%), GlaxoSmithKline (6%) and Prestige Brands Holdings (5%).

Industry Prospects

Dermatologicals in the US is expected to grow by a CAGR of 1% in constant retail value terms over 2014-2019 to reach US$3.3 billion – a notable deceleration compared with the review period performance. Dermatologicals is a rather mature environment that is often limited by cyclical trends and a high level of private label penetration. Additionally, the recovery of certain brands, especially those produced by Novartis, provided a boost over the past several years, but the effect has waned and will continue to do so throughout the forecast period. These factors lend to difficult market conditions, ultimately putting downwards pressure on growth prospects.

Report Overview

Discover the latest market trends and uncover sources of future market growth for the Medicated Skin Care industry in USA with research from Euromonitor's team of in-country analysts.

Find hidden opportunities in the most current research data available, understand competitive threats with our detailed market analysis, and plan your corporate strategy with our expert qualitative analysis and growth projections.

If you're in the Medicated Skin Care industry in USA, our research will save you time and money while empowering you to make informed, profitable decisions.

The Medicated Skin Care in USA market research report includes:

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- Dermatologicals in France
- Dermatologicals in Thailand
- Dermatologicals in Romania
- Dermatologicals in Brazil
- Dermatologicals in Belgium